Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
137,278,139
-
Number of holders
-
226
-
Total 13F shares, excl. options
-
88,385,448
-
Shares change
-
+2,390,719
-
Total reported value, excl. options
-
$2,056,730,043
-
Value change
-
+$54,021,550
-
Put/Call ratio
-
67%
-
Number of buys
-
114
-
Number of sells
-
-99
-
Price
-
$23.27
Significant Holders of Vir Biotechnology, Inc. - Common Stock (VIR) as of Q1 2023
264 filings reported holding VIR - Vir Biotechnology, Inc. - Common Stock as of Q1 2023.
Vir Biotechnology, Inc. - Common Stock (VIR) has 226 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 88,385,448 shares
of 137,278,139 outstanding shares and own 64% of the company stock.
Largest 10 shareholders include SB INVESTMENT ADVISERS (UK) LTD (18,319,938 shares), BlackRock Inc. (13,955,491 shares), VANGUARD GROUP INC (10,267,462 shares), Temasek Holdings (Private) Ltd (5,814,972 shares), STATE STREET CORP (5,384,163 shares), BAILLIE GIFFORD & CO (3,986,026 shares), ALLIANCEBERNSTEIN L.P. (2,748,845 shares), Point72 Asset Management, L.P. (1,683,100 shares), Avidity Partners Management LP (1,640,200 shares), and Bill & Melinda Gates Foundation (1,559,142 shares).
This table shows the top 226 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.